Aytu BioScience Inc.

0.5359+0.0080+1.52%Vol 120.25K1Y Perf -89.83%
Jun 28th, 2022 16:00 DELAYED
BID0.5000 ASK0.5400
Open0.5222 Previous Close0.5279
Pre-Market- After-Market0.54
 - -  - -%
Target Price
8.00 
Analyst Rating
Strong Buy 1.00
Potential %
1.39K 
Finscreener Ranking
★★★★+     57.51
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     42.75
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     44.68
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
1.74 
Earnings Rating
Neutral
Market Cap20.67M 
Earnings Date
16th May 2022
Alpha-0.07 Standard Deviation0.34
Beta-0.16 

Today's Price Range

0.52010.5400

52W Range

0.45005.38

5 Year PE Ratio Range

-1.50-0.2000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
7.65%
1 Month
-7.68%
3 Months
-52.87%
6 Months
-61.75%
1 Year
-89.83%
3 Years
-97.21%
5 Years
-99.98%
10 Years
-

TickerPriceChg.Chg.%
AYTU0.53590.00801.52
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.00
0.21
0.35
-
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
52.60
-47.90
-35.70
-289.70
-85.25
RevenueValueIndustryS&P 500US Markets
92.70M
2.40
126.83
105.62
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.41-0.2734.15
Q02 2022--0.44-
Q01 2022--0.33-
Q04 2021-0.16-0.67-318.75
Q03 2021-0.36-0.1752.78
Q02 2021-0.50-0.476.00
Q01 2021-0.60-0.4033.33
Q03 2020-3.90-1.5061.54
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.3186.86Positive
6/2022 QR-0.31--
6/2022 FY-2.58--
6/2023 FY-0.76--
Next Report Date-
Estimated EPS Next Report-0.41
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume120.25K
Shares Outstanding38.57K
Shares Float36.76M
Trades Count445
Dollar Volume63.81K
Avg. Volume561.15K
Avg. Weekly Volume290.58K
Avg. Monthly Volume345.99K
Avg. Quarterly Volume1.05M

Aytu BioScience Inc. (NASDAQ: AYTU) stock closed at 0.5279 per share at the end of the most recent trading day (a 1.66% change compared to the prior day closing price) with a volume of 154.56K shares and market capitalization of 20.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 75 people. Aytu BioScience Inc. CEO is Joshua R. Disbrow.

The one-year performance of Aytu BioScience Inc. stock is -89.83%, while year-to-date (YTD) performance is -60.9%. AYTU stock has a five-year performance of -99.98%. Its 52-week range is between 0.45 and 5.38, which gives AYTU stock a 52-week price range ratio of 1.74%

Aytu BioScience Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.33, a price-to-sale (PS) ratio of 0.22, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -52.43%, a ROC of -88.33% and a ROE of -113.56%. The company’s profit margin is -85.25%, its EBITDA margin is -35.70%, and its revenue ttm is $92.70 Million , which makes it $2.40 revenue per share.

Of the last four earnings reports from Aytu BioScience Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Aytu BioScience Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aytu BioScience Inc. is Strong Buy (1), with a target price of $8, which is +1 392.82% compared to the current price. The earnings rating for Aytu BioScience Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aytu BioScience Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aytu BioScience Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.95, ATR14 : 0.06, CCI20 : -31.81, Chaikin Money Flow : -0.20, MACD : -0.03, Money Flow Index : 72.04, ROC : -6.13, RSI : 46.51, STOCH (14,3) : 42.34, STOCH RSI : 1.00, UO : 30.67, Williams %R : -57.66), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aytu BioScience Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aytu BioScience Inc.

Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets. The primary care portfolio includes Natesto, the only FDA-approved nasal formulation of testosterone, ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, Cefaclor, Karbinal ER, and Poly-Vi-Flor and Tri-Vi-Flor.

CEO: Joshua R. Disbrow

Telephone: +1 720 437-6580

Address: 373 Inverness Parkway, Englewood 80112, CO, US

Number of employees: 75

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

60%40%

Bearish Bullish

56%44%

News

Stocktwits